Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Paraneoplastic retinopathies (PR), including cancer-associated retinopathy (CAR) or the closely related melanoma-associated retinopathy (MAR) occur in a small subset of patients with retinal degeneration and systemic cancer. This autoimmune syndrome is characterized by sudden, progressive loss of vision in association with circulating anti-retinal autoantibodies. The PR syndromes are heterogeneous, may produce a number of ocular symptoms, and may be associated with several different neoplasms, including lung, breast, prostate, gynecological, and colon cancer, melanoma, and hematologic malignancies. We examined the onset of retinopathy in correlation to the diagnosis of cancer and the presence of specific anti-retinal autoantibodies in PR patients. In some patients without diagnosed malignant tumors, the onset of ocular symptoms and the presence of autoantibodies preceded the diagnosis of cancer by months to years, including anti-recoverin, anti-transducin-α, and anti-carbonic anhydrase II antibodies. Although anti-retinal autoantibodies may not be a good predictor of a specific neoplasm, they can be used as biomarkers for different subtypes of retinopathy. Identification of autoantibodies involved in autoimmune-mediated PR will help elucidate the mechanisms underlying the PR syndromes and develop targeted therapies for these sight-threatening disorders.

Original languageEnglish (US)
Pages (from-to)410-414
Number of pages5
JournalAutoimmunity Reviews
Volume8
Issue number5
DOIs
StatePublished - Mar 2009

Fingerprint

Autoantibodies
Virulence
Ocular Paraneoplastic Syndromes
Paraneoplastic Syndromes
Neoplasms
Recoverin
Transducin
Carbonic Anhydrase II
Retinal Degeneration
Hematologic Neoplasms
Colonic Neoplasms
Melanoma
Lung Neoplasms
Prostatic Neoplasms
Breast
Biomarkers
Antibodies
Therapeutics

Keywords

  • Anti-retinal autoantibodies
  • Autoimmune retinopathy
  • Cancer-associated retinopathy
  • Enolase
  • Recoverin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. / Adamus, Grazyna.

In: Autoimmunity Reviews, Vol. 8, No. 5, 03.2009, p. 410-414.

Research output: Contribution to journalArticle

@article{c3016ea75d994c4783c7093a1de01790,
title = "Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy",
abstract = "Paraneoplastic retinopathies (PR), including cancer-associated retinopathy (CAR) or the closely related melanoma-associated retinopathy (MAR) occur in a small subset of patients with retinal degeneration and systemic cancer. This autoimmune syndrome is characterized by sudden, progressive loss of vision in association with circulating anti-retinal autoantibodies. The PR syndromes are heterogeneous, may produce a number of ocular symptoms, and may be associated with several different neoplasms, including lung, breast, prostate, gynecological, and colon cancer, melanoma, and hematologic malignancies. We examined the onset of retinopathy in correlation to the diagnosis of cancer and the presence of specific anti-retinal autoantibodies in PR patients. In some patients without diagnosed malignant tumors, the onset of ocular symptoms and the presence of autoantibodies preceded the diagnosis of cancer by months to years, including anti-recoverin, anti-transducin-α, and anti-carbonic anhydrase II antibodies. Although anti-retinal autoantibodies may not be a good predictor of a specific neoplasm, they can be used as biomarkers for different subtypes of retinopathy. Identification of autoantibodies involved in autoimmune-mediated PR will help elucidate the mechanisms underlying the PR syndromes and develop targeted therapies for these sight-threatening disorders.",
keywords = "Anti-retinal autoantibodies, Autoimmune retinopathy, Cancer-associated retinopathy, Enolase, Recoverin",
author = "Grazyna Adamus",
year = "2009",
month = "3",
doi = "10.1016/j.autrev.2009.01.002",
language = "English (US)",
volume = "8",
pages = "410--414",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy

AU - Adamus, Grazyna

PY - 2009/3

Y1 - 2009/3

N2 - Paraneoplastic retinopathies (PR), including cancer-associated retinopathy (CAR) or the closely related melanoma-associated retinopathy (MAR) occur in a small subset of patients with retinal degeneration and systemic cancer. This autoimmune syndrome is characterized by sudden, progressive loss of vision in association with circulating anti-retinal autoantibodies. The PR syndromes are heterogeneous, may produce a number of ocular symptoms, and may be associated with several different neoplasms, including lung, breast, prostate, gynecological, and colon cancer, melanoma, and hematologic malignancies. We examined the onset of retinopathy in correlation to the diagnosis of cancer and the presence of specific anti-retinal autoantibodies in PR patients. In some patients without diagnosed malignant tumors, the onset of ocular symptoms and the presence of autoantibodies preceded the diagnosis of cancer by months to years, including anti-recoverin, anti-transducin-α, and anti-carbonic anhydrase II antibodies. Although anti-retinal autoantibodies may not be a good predictor of a specific neoplasm, they can be used as biomarkers for different subtypes of retinopathy. Identification of autoantibodies involved in autoimmune-mediated PR will help elucidate the mechanisms underlying the PR syndromes and develop targeted therapies for these sight-threatening disorders.

AB - Paraneoplastic retinopathies (PR), including cancer-associated retinopathy (CAR) or the closely related melanoma-associated retinopathy (MAR) occur in a small subset of patients with retinal degeneration and systemic cancer. This autoimmune syndrome is characterized by sudden, progressive loss of vision in association with circulating anti-retinal autoantibodies. The PR syndromes are heterogeneous, may produce a number of ocular symptoms, and may be associated with several different neoplasms, including lung, breast, prostate, gynecological, and colon cancer, melanoma, and hematologic malignancies. We examined the onset of retinopathy in correlation to the diagnosis of cancer and the presence of specific anti-retinal autoantibodies in PR patients. In some patients without diagnosed malignant tumors, the onset of ocular symptoms and the presence of autoantibodies preceded the diagnosis of cancer by months to years, including anti-recoverin, anti-transducin-α, and anti-carbonic anhydrase II antibodies. Although anti-retinal autoantibodies may not be a good predictor of a specific neoplasm, they can be used as biomarkers for different subtypes of retinopathy. Identification of autoantibodies involved in autoimmune-mediated PR will help elucidate the mechanisms underlying the PR syndromes and develop targeted therapies for these sight-threatening disorders.

KW - Anti-retinal autoantibodies

KW - Autoimmune retinopathy

KW - Cancer-associated retinopathy

KW - Enolase

KW - Recoverin

UR - http://www.scopus.com/inward/record.url?scp=61349129241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349129241&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.01.002

DO - 10.1016/j.autrev.2009.01.002

M3 - Article

VL - 8

SP - 410

EP - 414

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 5

ER -